Covers: Humalog (lispro) · Novolog / NovoRapid (aspart) · Apidra (glulisine)
Rapid-acting insulin analogues — insulin lispro (Humalog), insulin aspart (Novolog/NovoRapid), and insulin glulisine (Apidra) — have an elimination half-life of approximately 1 hour following subcutaneous injection[1][2], with onset of glucose-lowering action at 10–15 minutes, peak effect at 1–2 hours, and duration of approximately 3–4 hours. These analogues are FDA-approved for mealtime (prandial) insulin replacement in type 1 and type 2 diabetes.
| Parameter | Value (SC) | Source |
|---|---|---|
| Elimination Half-Life | ~1 hour | FDA NDA 020563 (Humalog), NDA 020986 (Novolog)[1][2] |
| Onset of Action | 10–15 minutes | FDA NDA 020563, NDA 020986[1][2] |
| Time to Peak Effect (Tmax) | 1–2 hours | FDA NDA 020563, NDA 020986[1][2] |
| Duration of Action | 3–4 hours | FDA NDA 020563, NDA 020986[1][2] |
| Bioavailability (SC) | ~55–77% | FDA labels (varies by analogue and injection site) |
| Full Clearance (5 × t½) | ~5 hours | Calculated from label PK data |
| Primary Clearance Route | Receptor-mediated degradation; liver, kidney, muscle | FDA NDA 020563[1] |
| Standard Dosing | 0–15 min before meals (or immediately after) | FDA-approved labeling |
| Data Quality | Human RCT — FDA NDA 020563 (Humalog), NDA 020986 (Novolog), NDA 021629 (Apidra) | |
Rapid-acting insulin analogues have an elimination half-life of approximately 1 hour following subcutaneous injection, based on pharmacokinetic data from FDA-approved prescribing information for Humalog (NDA 020563) and Novolog (NDA 020986).[1][2] This is substantially shorter than regular human insulin (~2 hours SC), enabling faster onset and earlier peaking that better matches postprandial glucose excursions.
Half-life data for insulin analogues is derived from euglycaemic clamp studies — a gold-standard pharmacodynamic method in which blood glucose is maintained at a fixed target while exogenous insulin is infused and glucose infusion rate (GIR) is used to quantify insulin action. Plasma insulin concentrations are measured serially to calculate pharmacokinetic parameters including t½, Tmax, and area under the curve (AUC).
Rapid-acting insulin's plasma half-life (~1 hour) describes how quickly the hormone clears from circulation. The duration of glucose-lowering action (3–4 hours) is substantially longer. This is because insulin receptor signalling, GLUT4 translocation to cell membranes, and hepatic glucose production suppression continue downstream of peak plasma insulin — the biological cascade persists after the hormone itself clears. Understanding this distinction is critical to avoiding hypoglycaemia from "insulin stacking" (injecting a new dose before the previous dose's action has fully resolved).
| Half-Lives Elapsed | Time After SC Injection | % Remaining in Plasma | Clinical Note |
|---|---|---|---|
| 1 | ~1 hour | 50% | Peak glucose-lowering effect typically occurring |
| 2 | ~2 hours | 25% | Still active glucose-lowering; hypoglycaemia risk if meal not consumed |
| 3 | ~3 hours | 12.5% | Late action tail; risk if next meal delayed |
| 4 | ~4 hours | 6.25% | Action largely resolved for most individuals |
| 5 (threshold) | ~5 hours | ~3% | Pharmacologically negligible plasma levels |
The 10–15 minute onset and 1–2 hour peak of rapid-acting analogues are specifically engineered to match the 30–60 minute postprandial glucose peak. Injecting 0–15 minutes before a meal allows plasma insulin to rise concurrently with blood glucose, blunting the postprandial spike. Some patients using very-fast-acting formulations (Fiasp aspart, Lyumjev lispro) inject at meal start or immediately after.[3]
A missed rapid-acting insulin dose results in uncontrolled postprandial hyperglycaemia. Because plasma clearance occurs within ~5 hours, a missed mealtime dose cannot be compensated by doubling the next mealtime dose — this would create dangerous insulin stacking. Correction dosing guidance must come from a treating physician.
| Insulin Type | Examples | Half-Life SC | Onset | Peak | Duration |
|---|---|---|---|---|---|
| Rapid-acting analogue | Lispro, Aspart, Glulisine | ~1 hour | 10–15 min | 1–2 h | 3–4 h |
| Regular (short-acting) | Humulin R, Novolin R | ~2 hours | 30–60 min | 2–4 h | 5–8 h |
| NPH (intermediate) | Humulin N, Novolin N | ~4–6 hours | 1–2 h | 4–8 h | 12–18 h |
| Glargine (long-acting) | Lantus, Basaglar, Toujeo | ~12–19 hours | 1–2 h | Peakless | ~24 h |
| Route | Half-Life | Onset | Notes |
|---|---|---|---|
| Subcutaneous (abdomen) | ~1 hour | 10–15 min | Most common route; abdomen fastest absorption |
| Subcutaneous (thigh/arm) | ~1 hour | Slightly slower than abdomen | Site variability affects Tmax by 20–30 min |
| Intravenous (IV) | ~5–15 min | Immediate | Hospital/ICU use only; requires continuous monitoring |
| Continuous SC infusion (pump) | Equivalent to SC bolus | 10–15 min | Basal: micro-boluses; Bolus: pre-meal |
| Intramuscular (IM) | Faster than SC | ~10 min | Not standard; faster absorption than SC |
Exogenous insulin is not included in standard WADA anti-doping immunoassay panels or routine workplace drug screens. WADA lists insulin as a prohibited substance in sport (S4 — Hormone and Metabolic Modulators) and requires athletes to file a Therapeutic Use Exemption (TUE) if insulin is medically necessary.
WADA-accredited laboratories can detect exogenous insulin analogues (lispro, aspart, glulisine) in urine using LC-MS/MS, distinguishing them from endogenous human insulin and from each other by their unique amino acid substitutions. C-peptide suppression testing is used to assess endogenous insulin secretion. Detection windows depend on dose and analogue, but urine detection is generally possible within 24 hours of the last dose for standard analytical methods.
Native human insulin self-associates into hexamers at physiological concentrations used in vials and pens. After subcutaneous injection, hexamers must dissociate into dimers and then monomers before absorption into the bloodstream — this step is the rate-limiting delay responsible for regular insulin's 30–60 minute onset. Rapid-acting analogues address this through amino acid substitutions that disrupt hexamer self-association:[1][2]
Insulin lispro (Humalog) inverts the positions of proline (B28) and lysine (B29) relative to human insulin. Insulin aspart (Novolog) substitutes proline at B28 with aspartic acid, introducing charge repulsion between monomers. Insulin glulisine (Apidra) substitutes asparagine at B3 with lysine and lysine at B29 with glutamic acid. All three modifications reduce self-association, shifting the equilibrium toward monomers at the injection site, accelerating absorption into capillaries, and shortening Tmax to 1–2 hours vs 2–4 hours for regular insulin.
Clearance occurs primarily via receptor-mediated endocytosis at insulin receptors in hepatocytes, renal tubular cells, and muscle cells, followed by lysosomal degradation of the insulin-receptor complex. Approximately 60% of insulin presented to the liver is extracted in a single pass.[1]
Log mealtime insulin doses and model plasma concentration curves based on the ~1-hour half-life. See onset, peak, and action tail. On-device. No data shared externally.
Download Free — iOSThe Halflife app tracks rapid-acting insulin alongside 44 other compounds — all with citation-backed pharmacokinetic data. Free on iOS.
Download on the App Store